Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]
In development [GID-TA10579] Expected publication date: 19 October 2022
Search results
479 results
-
-
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]
In development [GID-TA10829] Expected publication date: 01 June 2022
-
Teduglutide for treating short bowel syndrome [ID3937]
In development [GID-TA10842] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma [ID3760]
In development [GID-TA10629] Expected publication date: 19 January 2023
-
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]
In development [GID-TA10563] Expected publication date: TBC
-
Gout: diagnosis and management
In development [GID-NG10151] Expected publication date: 13 June 2022
-
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management
In development [GID-NG10185] Expected publication date: 23 August 2023
-
Semaglutide for managing overweight and obesity [ID3850]
In development [GID-TA10765] Expected publication date: 30 March 2022
-
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]
In development [GID-TA10812] Expected publication date: 01 February 2023
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: 25 January 2023
-
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]
In development [GID-TA10504] Expected publication date: TBC
-
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]
In development [GID-TA10669] Expected publication date: 23 November 2022
-
Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]
In development [GID-TA10825] Expected publication date: 29 July 2022
-
Pralsetinib for RET fusion-positive advanced non-small-cell lung cancer [ID3875]
In development [GID-TA10770] Expected publication date: 27 April 2022
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]
In development [GID-TA10804] Expected publication date: TBC
-
Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]
In development [GID-TA10342] Expected publication date: TBC
-
177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
In development [GID-TA10730] Expected publication date: 21 September 2022
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: TBC
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Cardiac transplantation (rejection) - everolimus [ID114]
In development [GID-TAG232] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168
In development [GID-TA10208] Expected publication date: TBC
-
Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]
In development [GID-TA10477] Expected publication date: TBC
-
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]
In development [GID-TA10430] Expected publication date: TBC
-
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after at least 2 prior treatments [ID1083]
In development [GID-TA10260] Expected publication date: 22 June 2022
-
Faricimab for treating wet age-related macular degeneration [ID3898 ]
In development [GID-TA10799] Expected publication date: 10 August 2022
-
Relugolix with oestradiol and norethisterone acetate for treating uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 22 June 2022
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 25 May 2022
-
Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]
In development [GID-TA10732] Expected publication date: 21 September 2022
-
Faricimab for treating diabetic macular oedema [ID3899]
In development [GID-TA10798] Expected publication date: 22 June 2022
-
Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]
In development [GID-TA10693] Expected publication date: 20 July 2022
-
Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]
In development [GID-TA10482] Expected publication date: 12 October 2022
-
Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]
In development [GID-TA10697] Expected publication date: TBC
-
Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]
In development [GID-TA10782] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]
In development [GID-TA10740] Expected publication date: 13 July 2022
-
Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]
In development [GID-TA10767] Expected publication date: TBC
-
Falls in older people: assessing risk and prevention
In development [GID-NG10228] Expected publication date: 01 March 2024
-
Tisagenlecleucel for treating relapsed or refractory aggressive diffuse large B-cell lymphoma after 1 systemic therapy [ID3974]
In development [GID-TA10859] Expected publication date: TBC
-
Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]
In development [GID-TA10890] Expected publication date: 25 May 2022
-
Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]
In development [GID-TA10698] Expected publication date: TBC
-
Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]
In development [GID-TA10385] Expected publication date: TBC
-
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]
In development [GID-TA10536] Expected publication date: TBC
-
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]
In development [GID-TA10691] Expected publication date: 13 July 2022
-
Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults
In development [GID-NG10141] Expected publication date: 20 April 2022
-
Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]
In development [GID-TAG508] Expected publication date: TBC
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
In development [GID-TA10751] Expected publication date: 13 July 2022
-
Weight Management: preventing, assessing and managing overweight and obesity (update)
In development [GID-NG10182] Expected publication date: 22 June 2023
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
In development [GID-TA10786] Expected publication date: TBC
-
Tezepelumab for treating severe asthma [ID3910]
In development [GID-TA10796] Expected publication date: TBC
-
Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: 19 October 2022
-
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
In development [GID-TA10089] Expected publication date: 15 November 2017